Immunocompromised patients are at high risk of invasive fungal infections (IFI), in particular
those with haematological malignancies undergoing remission-induction chemotherapy for …

Purpose Voriconazole, an antifungal drug, is metabolized by a cytochrome P450 isozyme.
Increased adverse effects are observed in Asians because of the high rate of poor …

Voriconazole, a triazole antifungal agent, demonstrates wide interpatient variability in serum
concentrations, due in part to variant CYP2C19 alleles. Individuals who are CYP2C19 …

Posaconazole is a second-generation triazole agent with a potent and broad antifungal
activity. In addition to the oral suspension, a delayed-release tablet and intravenous …

Introduction: Therapeutic drug monitoring (TDM) has been shown to optimize the
management of invasive fungal infections (IFIs), particularly for select antifungal agents with …

A number of life-saving drugs require therapeutic drug monitoring (TDM) for safe and
effective use. Currently, however, TDM is performed using sophisticated analytical …

Voriconazole (VCZ) use is limited by its narrow therapeutic range and significant interpatient
variability in exposure. This study aimed to assess (i) the impact of CYP2C19 genotype on …

Chronic lymphocytic leukaemia (CLL) is the most common leukaemia with infections a
leading cause of morbidity and mortality. Recently there has been a paradigm shift from the …

Objectives This analysis evaluated the variability of isavuconazole plasma concentrations
between subjects and between sampling times, and assessed their relationship to outcomes …

Background Therapeutic drug monitoring (TDM) aims to minimize the clinical impact of
posaconazole and voriconazole pharmacokinetic variability. However, its benefits on clinical …